CK-0045 is under clinical development by CytoKi Pharma and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CK-0045’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CK-0045 overview
CytoKi Pharma overview
CytoKi Pharma is a clinical-stage biotechnology company. It develops medicines to treat metabolic diseases and conditions characterized by epithelial injury. The company’s activities involve harnessing the innate biology of Interleukin-22 (IL-22) to address these diseases. Its lead product, CK-0045, is a long-acting IL-22 analog currently undergoing clinical evaluation. Cytoki Pharma products are aimed at addressing obesity, type 2 diabetes and inflammatory bowel disease. The company’s products are designed for use in the healthcare industry for patients suffering from the aforementioned conditions. Cytoki Pharma is headquartered in Søborg, Denmark.
For a complete picture of CK-0045’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
